✨
AI Summary & Key Takeaways
AI Insight⚡ TL;DR(Too Long; Didn't Read)
However, we observed the first case of DAA treatment failure in HCV patient who was co-infected with H.
📌 3 Key Takeaways
🎯
Objective & Hypothesis:Newly developed direct-acting anti-viral drugs act as a major breakthrough in the area of HCV therapeutics.
📊
Key Findings & Data:Accumulating evidence suggest that more than 99% patients achieve sustained virological response after receiving sofosbuvir-based therapy.
💡
Conclusion & Impact:However, we observed the first case of DAA treatment failure in HCV patient who was co-infected with H.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters
Özet
Newly developed direct-acting anti-viral drugs act as a major breakthrough in the area of HCV therapeutics. Accumulating evidence suggest that more than 99% patients achieve sustained virological response after receiving sofosbuvir-based therapy. However, we observed the first case of DAA treatment failure in HCV patient who was co-infected with H. Pylori.
🔖
Cite This Article
WAHID, B. (2019). Treatment response of sofosbuvir in HCV virus/ Helicobacter pylori co-infected patient a case report. Gülhane Tıp Dergisi, Cilt: 61 - Sayı: 4, 189–191. https://ajindex.com/articles/161840